1. Home
  2. VKTX vs PAY Comparison

VKTX vs PAY Comparison

Compare VKTX & PAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • PAY
  • Stock Information
  • Founded
  • VKTX 2012
  • PAY 2004
  • Country
  • VKTX United States
  • PAY United States
  • Employees
  • VKTX N/A
  • PAY N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • PAY Computer Software: Prepackaged Software
  • Sector
  • VKTX Health Care
  • PAY Technology
  • Exchange
  • VKTX Nasdaq
  • PAY Nasdaq
  • Market Cap
  • VKTX 3.5B
  • PAY 4.0B
  • IPO Year
  • VKTX 2015
  • PAY 2021
  • Fundamental
  • Price
  • VKTX $40.03
  • PAY $37.49
  • Analyst Decision
  • VKTX Strong Buy
  • PAY Buy
  • Analyst Count
  • VKTX 13
  • PAY 7
  • Target Price
  • VKTX $86.92
  • PAY $36.50
  • AVG Volume (30 Days)
  • VKTX 4.6M
  • PAY 766.7K
  • Earning Date
  • VKTX 07-23-2025
  • PAY 08-04-2025
  • Dividend Yield
  • VKTX N/A
  • PAY N/A
  • EPS Growth
  • VKTX N/A
  • PAY 69.57
  • EPS
  • VKTX N/A
  • PAY 0.44
  • Revenue
  • VKTX N/A
  • PAY $1,044,760,000.00
  • Revenue This Year
  • VKTX N/A
  • PAY $27.45
  • Revenue Next Year
  • VKTX $338.60
  • PAY $20.34
  • P/E Ratio
  • VKTX N/A
  • PAY $85.20
  • Revenue Growth
  • VKTX N/A
  • PAY 49.35
  • 52 Week Low
  • VKTX $18.92
  • PAY $19.53
  • 52 Week High
  • VKTX $81.73
  • PAY $40.43
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 69.97
  • PAY 77.02
  • Support Level
  • VKTX $39.35
  • PAY $33.21
  • Resistance Level
  • VKTX $41.68
  • PAY $34.49
  • Average True Range (ATR)
  • VKTX 2.06
  • PAY 1.33
  • MACD
  • VKTX 0.56
  • PAY 0.95
  • Stochastic Oscillator
  • VKTX 84.10
  • PAY 95.99

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About PAY Paymentus Holdings Inc.

Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.

Share on Social Networks: